RxSight, Inc. Financing Receivable, Unamortized Loan Fee (Cost)
RxSight, Inc. (RXST) had Financing Receivable, Unamortized Loan Fee (Cost) of $100.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes
us-gaap:FinancingReceivableUnamortizedLoanFeeCost · last filed 2023-05-09
- 2023-03-31: Financing Receivable, Unamortized Loan Fee (Cost) $100.00K.
- 2022-12-31: Financing Receivable, Unamortized Loan Fee (Cost) $100.00K.
- 2022-09-30: Financing Receivable, Unamortized Loan Fee (Cost) $100.00K.
- 2022-06-30: Financing Receivable, Unamortized Loan Fee (Cost) $100.00K.
| Period end | Financing Receivable, Unamortized Loan Fee (Cost) |
|---|---|
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $100.00K 10-K · filed 2023-03-06 |
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |